The Amylin Wave: How a Forgotten Diabetes Hormone Became Obesity's Second Pillar

GLP-1 drugs raised the ceiling on obesity treatment. Amylin is being designed to fix the floor. Most people who start a GLP-1 do not stay on it: a real-world Truveta analysis of 125,000 patients found 64.8% of non-diabetic users discontinued within a year, and a Prime Therapeutics study put three-year persistence at 8%. The two main reasons are gastrointestinal side effects and the wear of weekly injection. Amylin analogs, a class of peptides that mimic the satiety hormone co-secreted with insulin, hit the same satiety pathways through a different receptor and produce double-digit weight loss with a side-effect profile that looks more like placebo than like semaglutide.

The first attempt to use this biology was pramlintide, FDA-approved in 2005 as Symlin. It required three injections a day and produced modest weight loss, and it failed commercially. Twenty years later, the engineering caught up. Cagrilintide, petrelintide, eloralintide, and zenagamtide are once-weekly molecules with the same physiology and a vastly cleaner profile. Forty amylin programs are now active, the four largest obesity sponsors all have one in or near Phase 3, and the strategic bet is that combination with GLP-1, already proven in Novo's CagriSema, becomes the format that turns obesity drugs into chronic-care franchises rather than ninety-day discontinuations.

Amylin is a 37-amino-acid peptide secreted alongside insulin from the same beta cells, at a molar ratio of roughly one amylin molecule for every ten to a hundred insulin molecules. Its job in healthy physiology is to slow gastric emptying, suppress post-meal glucagon, and tell the brain a meal is finished. The pharmacology has been known since the late 1980s. The first synthetic analog, pramlintide, won FDA approval on March 16, 2005 as Symlin, indicated as an injectable adjunct to mealtime insulin in type 1 and insulin-using type 2 diabetes.

It did not take off. The dose schedule was three injections a day, given separately from insulin because the two could not be combined in a syringe. Early nausea was common, and the weight effect was modest. Amylin Pharmaceuticals, the developer, was acquired by Bristol-Myers Squibb and AstraZeneca in 2012 mostly for its exenatide GLP-1 franchise, not for Symlin. The amylin molecule itself was not the problem; the format was. What broke the commercial case was dosing burden plus an early GI penalty, in an era when the alternative was a weekly Byetta injection that delivered better weight loss with less hassle.

That history matters because it sets up what the modern amylin renaissance had to solve. It had to convert a three-times-daily peptide into a once-weekly drug, smooth the tolerability profile, and produce weight loss competitive with GLP-1. Cagrilintide, approved as the amylin component of Novo's CagriSema combination, did all three.

The mechanistic argument for amylin is that it activates different brain neurons than GLP-1 does, even though both signal satiety. GLP-1 receptor agonists drive their effects through dorsal vagal complex and area postrema neurons that also mediate nausea and vomiting. A landmark 2021 Neuron paper from the Liberles lab at Harvard mapped the area postrema in detail and found that GLP-1 and amylin act on largely separate populations of excitatory neurons. The GLP-1-receptor-positive cells overlap heavily with the area postrema nausea circuit. The calcitonin-receptor-positive cells, which amylin engages through receptor-modifying protein complexes, are a distinct group.

That anatomy predicts what petrelintide's Phase 2 ZUPREME-1 trial showed. The trial enrolled 493 adults with overweight or obesity and followed them for 42 weeks. The maximally effective dose produced 10.7% mean weight loss versus 1.7% on placebo, and across all petrelintide arms, vomiting was reported in 3.0% of patients, lower than the 6.2% rate on placebo. There was no vomiting at all in the highest-dose group. By comparison, the STEP 1-3 pooled semaglutide data show nausea in 43.9% of patients and vomiting in 24.5%.

The mechanistic claim is still a model. The Neuron paper is rodent work, and the human translation is biologically grounded rather than directly proven. A 2026 Frontiers review explicitly noted that central-satiety effects may predominate over peripheral-emetic pathways in amylin, but that mechanistic data in humans remain limited. What the ZUPREME-1 numbers establish is that whatever the precise reason, the clinical pattern is what the model predicts: a peptide that hits satiety hard, but does not activate the vomiting center to the same degree.

Tolerability is the central pitch of the amylin class because the real-world data on GLP-1 retention are bad. Truveta's analysis of 125,474 GLP-1 starters in 2025 found one-year discontinuation of 64.8% among patients without diabetes and 46.5% with diabetes, with GI adverse events as a significant hazard driver (HR 1.19 to 1.38). Prime Therapeutics tracked obesity-without-diabetes patients for three years and found 8.1% persistence; for Wegovy it was 14.3%, for Victoza 2.5%. Industry-wide, between 30% and 40% of patients who quit GLP-1s cite nausea, vomiting, or appetite-related effects as the trigger.

Petrelintide's ZUPREME-1 took an unusual shot at this. Adverse-event-driven discontinuation in the maximally effective arm was 4.8% versus 4.9% on placebo. Total trial withdrawal was 8.4% on drug versus 13.6% on placebo, meaning more patients quit the placebo arm than quit the active drug. Only 1.5% of participants left the trial because of a GI side effect. Lilly's selective amylin agonist eloralintide showed a similar pattern in Phase 2: 9.5% to 20.1% weight loss across doses, with the lowest-dose arms producing AE rates indistinguishable from placebo.

That profile reorders the comparison. On peak weight loss, amylin monotherapy still trails the strongest incretins: 10.7% (petrelintide) and 20.1% (eloralintide high dose) versus 28.3% for retatrutide and 22.7% for CagriSema. But on patients who actually stay on the drug long enough to lose that weight, the gap closes in the other direction. Roche's chief medical officer Manu Chakravarthy framed it at ADA 2026: "You're getting double-digit weight loss, very clinically meaningful, and you get this placebo-like tolerability."

The top of the pipeline holds four assets in or near registrational trials. Novo Nordisk's CagriSema, the fixed-dose combination of cagrilintide with semaglutide, was filed with the FDA in December 2025 and would become the first amylin-plus-GLP-1 combination approval if cleared. REDEFINE 1 in non-diabetic obesity delivered 22.7% mean weight loss at 68 weeks, and at ADA 2026 the REIMAGINE 1, 2, and 3 trials in type 2 diabetes reported HbA1c reductions of 1.8% to 2.33% and weight loss of 12.0% to 14.2%. REIMAGINE 2's head-to-head against semaglutide alone showed 14.2% versus 10.2% weight loss and a 1.91% versus 1.75% HbA1c drop in 2,713 patients over 68 weeks.

Petrelintide (Zealand Pharma, licensed to Roche) advances to Phase 3 in the second half of 2026, with the ZUPREME-1 data behind it and a planned Phase 2 fixed-dose combination with Roche's GLP-1/GIP agonist enicepatide starting mid-year. Roche projected $9 billion in peak annual sales for the combined obesity franchise on its Q1 2026 earnings call, with petrelintide alone above $3 billion. Eli Lilly's eloralintide reported Phase 2 results in November 2025 showing weight loss from 9.5% to 20.1% across doses, with Phase 3 monotherapy starting by end-2025 and a Phase 2 combination with tirzepatide already enrolling. Novo's zenagamtide, the unimolecular GLP-1-amylin co-agonist formerly known as amycretin, reported Phase 2 data at ADA 2026: 14.6% weight loss and a 1.71% HbA1c drop at the 40 mg dose in type 2 diabetes, with 89% of patients reaching an HbA1c under 7%. Phase 3 starts in the second half of 2026.

Behind those four, the pipeline explores the next set of differentiators. Pfizer's MET-233i, acquired in the $4.9 billion Metsera deal, is a once-monthly amylin analog with a 19-day half-life designed to combine with the monthly GLP-1 berobenatide. AbbVie partnered with Gubra in March 2025 for $350 million upfront and up to $1.875 billion in milestones for GUB-014295, a long-acting amylin-calcitonin dual agonist that posted 7.75 to 9.79% weight loss in Phase 1. Verdiva Bio is developing an oral amylin analog (VRB-103) and a unimolecular GLP-1-amylin co-agonist (VRB-104), both preclinical at ADA 2026. Alveus Therapeutics launched in January 2026 with $160 million; its ALV-200 is a selective amylin receptor 3 agonist still in IND-enabling work. A PatentVest field review counted forty active amylin programs in early 2026, up from fifteen in 2022, with deal value exceeding $19 billion.

Almost every late-stage amylin program is being developed with combination in mind, not as monotherapy. The strategic logic is straightforward: amylin alone delivers solid weight loss with great tolerability, but the highest numbers in the field belong to combinations. CagriSema's 22.7% in REDEFINE 1 and zenagamtide's 22% in Phase 1b/2a are both unimolecular or fixed-dose combinations of GLP-1 plus amylin biology. The combination expands the satiety signal across two distinct receptor classes, which appears to be more than additive in preclinical work; a 2019 Scientific Reports paper showed salmon calcitonin plus liraglutide produced synergistic, not additive, reductions in food intake and weight.

The four largest obesity pipelines have now committed to this thesis. Novo runs both routes: CagriSema as fixed-dose combination and zenagamtide as unimolecular. Roche is running petrelintide plus enicepatide as a Phase 2 fixed-dose combination starting mid-2026. Lilly is testing eloralintide plus tirzepatide in Phase 2 and has disclosed work on a single-molecule quintuple agonist that includes amylin and calcitonin activities alongside GLP-1, GIP, and glucagon. Pfizer's Metsera structure pairs the GLP-1 MET-097i with the amylin MET-233i for monthly dosing, with the CVR payouts in the acquisition explicitly tied to combo approval milestones.

There is also a body-composition argument for combining. Roughly 45% of semaglutide-induced weight loss is lean mass and 25% of tirzepatide's is, with amylin hypothesized to attenuate that loss because it acts on appetite without driving the same level of energy expenditure. The data are limited, but the marketing emphasis on body composition is consistent across the four pipelines, and Boehringer's pre-specified body-composition analysis of survodutide presented at ADA reinforced the broader argument that the obesity field is moving from raw weight loss as the only endpoint toward fat-loss-with-lean-preservation as the relevant question.

Amylin is being designed for two specific populations the GLP-1 market does not serve well. The first is the patient who cannot tolerate GLP-1 side effects. Industry estimates put that group at 30 to 40 percent of all GLP-1 starters. Medical Daily framed petrelintide at ADA 2026 as the option for exactly this cohort. The second is the patient who plateaus on monotherapy and needs a way to push past the GLP-1 efficacy ceiling without dose-escalating into worse side effects, which is the combination case.

There is a third, quieter market: the people who never start a GLP-1 because they are intimidated by the side-effect profile or want a non-incretin option for biological reasons. BMO's Evan Seigerman put the broader argument plainly: "Amylin is going to be an important target. There are still patients who don't" respond well to GLP-1s. The combined size of these populations is one of the reasons the obesity market projections keep climbing: RBC and Leerink see a $158 billion market by 2032, with the implicit assumption that the addressable patient base expands as tolerability barriers come down.

Most of the durability data are still ahead. Petrelintide's longest readout is 42 weeks. Eloralintide's is 48. CagriSema's longest published trial is 68 weeks. Whether the tolerability advantage translates into the multi-year persistence that defines a chronic-care market is the central open question, and the early hint from CagriSema's flexible-dosing data is mixed: in REDEFINE 1, only 57% of patients reached the top dose, suggesting tolerability still constrains real-world use even within a class designed around tolerability.

The head-to-head against best-in-class GLP-1 is also thin. CagriSema beat semaglutide alone, but no amylin or amylin-combination has tested against tirzepatide or retatrutide in a randomized trial. The Roche $9 billion peak-sales projection assumes the class can take meaningful share from the established Lilly and Novo franchises, which several sell-side analysts have flagged as optimistic. Cardiovascular outcomes data, the second-line case that semaglutide built with SELECT and FLOW, will not exist for amylin combinations until late this decade.

The mechanistic gap matters too. The cleanest evidence for differential brain-neuron targeting is rodent work. Petrelintide's no-vomiting profile is striking but has not yet been published in a peer-reviewed journal. CagriSema's combination story is real, but the field has not yet seen whether amylin-only monotherapy, without GLP-1, holds up over multiple years in a real-world weight-loss-maintenance setting. None of this means the class will not work. It means the case rests on tolerability so far, with the long-term efficacy and durability story being written through 2027 and 2028.

Amylin was the right biology with the wrong format in 2005. Twenty years of formulation work changed that, and in 2026 the field is shipping the result. CagriSema is at the FDA, petrelintide and eloralintide and zenagamtide are advancing into Phase 3, Roche and Lilly and Pfizer are pairing them with their flagship GLP-1s, and the deal value behind the class has crossed $19 billion. The argument is not that amylin will replace GLP-1, but that it will become the second pillar that sits beside it: the option for patients who quit on side effects, the second mechanism in fixed-dose combinations that push efficacy past monotherapy ceilings, and the differentiator that separates a 90-day prescription from a chronic-care franchise.

The limits are honest. Peak weight loss is below the best triagonists. Long-term durability is unproven. The cleanest tolerability data are from one Phase 2 trial that has not yet been peer-reviewed. But the direction of travel is consistent across four of the world's largest obesity programs, the FDA is reviewing a combination, and the next eighteen months will produce more Phase 3 readouts than any previous obesity-drug class in clinical history. The market is voting with both deal value and clinical investment that amylin is the answer to GLP-1's worst real-world problem.